Intravenous Glutathione is NOT Indicated for Non-Alcoholic Fatty Liver Disease
Intravenous glutathione should not be used for the treatment of non-alcoholic fatty liver disease (NAFLD), as there is no FDA-approved indication for this use, no established dosing regimen, and no high-quality evidence demonstrating benefit on clinically meaningful outcomes such as mortality, progression to cirrhosis, or quality of life.
Critical Evidence Against Use
FDA Drug Label Explicitly Prohibits This Use
The only FDA-approved glutathione IV formulation (BSS PLUS®) is specifically labeled for intraocular irrigation during ophthalmic surgery only 1. The drug label explicitly states: "NOT FOR INJECTION OR INTRAVENOUS INFUSION" and warns that it is "for reconstitution of irrigation solution only" 1. This represents a fundamental contraindication to systemic IV administration for any indication, including NAFLD.
Absence from Evidence-Based Guidelines
The 2022 BASL/BSG consensus guidelines for NAFLD management—the most recent and comprehensive quality standards for NAFLD care—make no mention of glutathione therapy in their evidence-based recommendations 2. These guidelines underwent rigorous GRADE methodology evaluation and modified Delphi consensus process with ≥80% agreement thresholds. The complete absence of glutathione from these authoritative recommendations is telling.
Limited and Low-Quality Supporting Evidence
Outdated and Methodologically Weak Studies
The only clinical evidence suggesting potential benefit comes from:
A 1995 Italian study showing improvements in liver enzymes (bilirubin, AST, ALT, GGT) with 1800 mg/day IV glutathione in chronic steatotic liver disease 3. However, this study is nearly 30 years old, predates modern NAFLD diagnostic criteria, and lacks data on hard outcomes like fibrosis progression, cirrhosis, or mortality.
A 2025 literature review examining only 3 small studies (total n=109 participants) that showed improvements in ALT and oxidative stress markers like 8-OHdG 4. The authors themselves acknowledge "small sample sizes and inconsistent protocols limit generalizability" and emphasize that "further large-scale RCTs are required to confirm GSH's efficacy" 4.
No Evidence for Mortality or Disease Progression Benefit
None of the available studies demonstrate that IV glutathione reduces:
- Liver-related mortality
- Progression to cirrhosis
- Development of hepatocellular carcinoma
- Need for liver transplantation
- Overall quality of life improvements
These are the outcomes that matter clinically, yet they remain completely unstudied.
Mechanistic Rationale Does Not Equal Clinical Efficacy
While oxidative stress plays a pathophysiological role in NAFLD progression 5, 6, and fatty livers show reduced glutathione levels 7, mechanistic plausibility does not substitute for clinical trial evidence. The leap from "oxidative stress is involved" to "IV antioxidant therapy improves outcomes" has failed repeatedly in medicine (e.g., vitamin E trials, beta-carotene in cancer prevention).
Common Pitfalls to Avoid
- Do not confuse oral glutathione supplementation with IV administration—they have different pharmacokinetics and safety profiles
- Do not extrapolate from acetaminophen toxicity studies 7—this is a completely different clinical scenario requiring N-acetylcysteine (a glutathione precursor), not glutathione itself
- Do not use off-label IV glutathione preparations marketed by compounding pharmacies without FDA approval or quality control
- Recognize that improving surrogate markers (like ALT or oxidative stress biomarkers) does not guarantee improvement in patient-centered outcomes
What Should Be Done Instead
For NAFLD management, focus on evidence-based interventions that actually reduce morbidity and mortality:
- Weight loss of 7-10% through lifestyle modification (diet and exercise)
- Management of metabolic comorbidities: diabetes control, dyslipidemia treatment, hypertension management
- Consideration of pharmacotherapy with agents that have demonstrated efficacy in clinical trials (e.g., pioglitazone for biopsy-proven NASH, GLP-1 receptor agonists)
- Cardiovascular risk reduction, as cardiovascular disease remains the leading cause of death in NAFLD patients 2
In the absence of FDA approval, guideline support, and high-quality evidence demonstrating benefit on hard clinical outcomes, IV glutathione cannot be recommended for NAFLD treatment in clinical practice.